Navigation Links
TYRX Appoints David Elliot, Jr. Chief Operating Officer
Date:12/2/2008

MONMOUTH JUNCTION, N.J., Dec. 2 /PRNewswire/ -- TYRX, Inc., a leader in the development and commercialization of convergent drug-device products, today announced the appointment of David Elliot, Jr. as Chief Operating Officer, responsible for commercial operations.

Mr. Elliot brings over 25 years of experience in the medical device industry. Mr. Elliot joins TYRX from Valam Corp., a privately held company focused on providing laser-based antimicrobial and vascular plaque destruction therapies, where he was President and CEO and remains a Board Director. Prior to Valam, Mr. Elliot was President, COO and Board Director of VistaCare, Inc., a publicly traded hospice care provider. Prior to VistaCare, Mr. Elliot was President, CEO and Board Director of The VASCLIP Company, a privately held medical device company that provides a less invasive surgical alternative to vasectomy. Prior to VASCLIP, Mr. Elliot was the Vice President of Sales and Marketing at Advanced Respiratory, Inc., a privately held company now owned by Hillenbrand Industries, Inc., that sold a proprietary FDA-approved medical device for patients with respiratory issues.

From 1996 to 2001, Mr. Elliot held two senior executive positions (Vice President, Global Marketing of Cardiac Rhythm Management and Director of Corporate Business Development) at St. Jude Medical. In 1987, Mr. Elliot began his career in healthcare executive management at Guidant Corporation, where during the following nine years he held different roles of escalating responsibility and was ultimately the director of Guidant Japan's Cardiac Rhythm Management division. Mr. Elliot earned a Bachelor of Arts in English from Connecticut College and an MBA from the University of Chicago.

"We are thrilled to have David join our management team," said Bill Edelman, President and CEO. "David's experience in the Cardiac Rhythm Management space, as well as his demonstrated track record of achievement in entrepreneurial settings, provides a powerful combination of skills to support the commercialization of our AIGISRx(TM) platform and to advance our forward looking strategies to bring TYRX's unique device/drug products to the market."

"I am excited about joining the TYRX team, which has already launched its first proprietary anti-bacterial device, AIGISRx, has entered a partnership for another, and has a multi-platform pipeline of additional proprietary technologies addressing postsurgical infection and other high cost implant associated morbidities," said Mr. Elliot. "I look forward to adding my business development and marketing experience to the impressive skill set already present at TYRX."

About TYRX, Inc.

TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGISRx(TM) Anti-Bacterial Envelope. AIGISRxCRMD contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in CRMD related endocarditis, including "superbugs" or MRSA. In addition, AIGISRxis intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June, 2008, AIGISRxhas been implanted in over 1,200 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.

For more information, please visit www.TYRX.com.

    CONTACT
    Bill Edelman
    President and Chief Executive Officer
    TYRX, Inc.
    732.246.8676
    william@TYRX.com


'/>"/>
SOURCE TYRX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Gym Source, ... of a new showroom at South Dixie Hwy in Miami, FL. , “We are ... Gym Source. “The new innovative in-store concept is designed to give clients a seamless ...
(Date:1/17/2017)... Los Angeles, CA (PRWEB) , ... January 17, ... ... conflicted and concerned by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting ... tragedies and magical moments that help everyone endure and pass through tough times, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks ... DRTV campaigns regarding the topic of Beauty and Personal Care. , ... What better way to commit to these changes than beginning with personal care and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS West, with multiple ... new office in San Clemente, California this month. Achieve TMS West is the ... treating individuals struggling with major depression. Depression impacts over 15 million adults in ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... to their offering. ... The global fluoropolymer market in the healthcare industry to grow ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, has been ... experts. The report covers the market landscape and its growth prospects ...
(Date:1/17/2017)... Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today announced ... pharmaceutical development at Tocagen, will present at Phacilitate Cell & ... Miami . Details of the ... ... - what to do when and why Date and Time: Wednesday, ...
(Date:1/17/2017)... 2017 Research and Markets has announced the ... Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug ... 2021" report to their offering. ... The global active pharmaceutical ingredients market is ... Billion in 2016, growing at a CAGR of 6.3% from 2016 ...
Breaking Medicine Technology: